Long COVID Patterns in the RECOVER-Adult Study
November 21, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Magnevist
Synonyms :
gadopentetate dimeglumine
Class :
Gadolinium-Containing Contrast Agent
Brand Name :
Magnevist
Synonyms :
gadopentetate dimeglumine
Class :
Gadolinium-Containing Contrast Agent
Dosage Forms & StrengthsÂ
Injectable SolutionÂ
50 mLÂ
100 mLÂ
Indicated for Magnetic resonance imaging Contrast Agent
0.2 ml/kg intravenous bolus
It should not exceed the infusion rate of 10 ml in 15 sec
0.1 mmol/kg (0.2 mL/kg) intravenous bolus administration at a rate of no more than 10 mL every 15 seconds. Dosing for patients weighing more than 286 pounds has not been investigated. To ensure that the medium is completely injected, the injection should be followed with a 5 mL saline flush
Dose Adjustments
Renal Dose Adjustments
In individuals with renal impairment who are on dialysis or with recent damage to the kidney, most usually within 48 hours following gadopentetate dimeglumine Injection. The risk of renal impairment severity increases with higher contrast dosage. Those patients require small doses to monitor renal function, and before taking this drug, it allows for sufficient contrast exit time. The elimination half-life in persons with mild to severe renal impairment is 3 to 4 hours. The elimination half-life in patients with severe renal impairment is approximately 11 hours
Gadopentetate dimeglumine can be dialyzed and eliminated through glomerular filtration. After three 3-hour dialysis sessions, roughly 97% of the administered dose is eliminated; each dialysis session removes around 70% of the circulating dose.
Gadopentetate dimeglumine is eliminated through the kidneys, even in people with reduced renal function. gadopentetate dimeglumine's serum half-life is prolonged in patients with compromised renal function. The mean serum elimination half-lives of a single intravenous dose of gadopentetate dimeglumine (0.1 mmol/kg) were 2.6 1.2 h, 4.2 2.0 h, and 10.8 6.9 h, respectively, in mildly (creatinine clearance, CLCR = 60 to 90 mL/min), moderately (CLCR = 30 to 60 mL/min), and severely (CLCR = 30 mL/min) impaired patients
0.1 mmol/kg (0.2 mL/kg) as a fast bolus intravenous administration at a rate of no more than 10 mL every 15 seconds. Dosing for people weighing more than 286 pounds has not been studied. To guarantee full administration of the medium, the injection should be followed by a 5 mL saline flush
Dose Adjustments
Renal Dose Adjustments
In individuals with renal impairment who are on dialysis or with recent damage to the kidney, most usually within 48 hours following gadopentetate dimeglumine Injection. The risk of renal impairment severity increases with higher contrast dosage. Those patients require small doses to monitor renal function, and before taking this drug, it allows for sufficient contrast exit time. The elimination half-life in persons with mild to severe renal impairment is 3 to 4 hours. The elimination half-life in patients with severe renal impairment is approximately 11 hours
Gadopentetate dimeglumine can be dialyzed and eliminated through glomerular filtration. After three 3-hour dialysis sessions, roughly 97% of the administered dose is eliminated; each dialysis session removes around 70% of the circulating dose.
Gadopentetate dimeglumine is eliminated through the kidneys, even in people with reduced renal function. gadopentetate dimeglumine's serum half-life is prolonged in patients with compromised renal function. The mean serum elimination half-lives of a single intravenous dose of gadopentetate dimeglumine (0.1 mmol/kg) were 2.6 1.2 h, 4.2 2.0 h, and 10.8 6.9 h, respectively, in mildly (creatinine clearance, CLCR = 60 to 90 mL/min), moderately (CLCR = 30 to 60 mL/min), and severely (CLCR = 30 mL/min) impaired patients
Dosage Forms & StrengthsÂ
Injectable SolutionÂ
50 mLÂ
100 mLÂ
Indicated for Magnetic resonance imaging Contrast Agent
Age >2 years
0.2 ml/kg intravenous bolus
It should not exceed the infusion rate of 10 ml in 15 sec
Age <2 years
Safety and efficacy not established
Safety and efficacy are not seen in pediatrics below 2 years
2–18 years: 0.1 mmol/kg (0.2 mL/kg) with a fast bolus intravenous infusion at a rate of no more than 10 mL every 15 seconds. Dosing for patients weighing more than 286 pounds has not been investigated. To ensure that the medium is completely injected, the injection should be followed with a 5 mL saline flush
Refer to adult dosingÂ
may have an increased QTc-prolonging effect when combined with gadobenate dimeglumine
may have an increased QTc-prolonging effect when combined with gadobenate dimeglumine
may have an increased QTc-prolonging effect when combined with gadobenate dimeglumine
may have an increased QTc-prolonging effect when combined with gadobenate dimeglumine
may have an increased QTc-prolonging effect when combined with gadobenate dimeglumine
Actions and Spectrum:Â
Actions:Â
Gadopentetate dimeglumine’s activity is linked to its use as a contrast agent in magnetic resonance imaging (MRI). It has no pharmacological effects on the body and instead works by interacting with the magnetic fields and radiofrequency pulses used in MRI.Â
Spectrum:Â
Gadopentetate dimeglumine’s principal purpose is to change the relaxation times of surrounding water molecules, which improves contrast in MRI imaging. It decreases the T1 (longitudinal) relaxation period of protons (hydrogen nuclei) in water molecules, resulting in higher signal intensity in T1-weighted MRI images. During diagnostic imaging, the enhanced contrast allows medical personnel to better visualize and differentiate between distinct tissues and organs.Â
Frequency not definedÂ
Localized pain at the site of injectionÂ
DizzinessÂ
NauseaÂ
HeadacheÂ
Loss of appetiteÂ
ChillsÂ
Increased thirstÂ
Stuffy noseÂ
NumbnessÂ
FlushingÂ
Feeling unusually hotÂ
Sore throatÂ
Black Box Warning:Â
Gadolinium-based contrast agents (GBCAs) enhance the risk of NSF in individuals who have impaired drug elimination. In these patients, avoid using GBCAs unless the diagnostic information is critical and not available with non-contrasted MRI or other modalities. NSF can cause deadly or disabling fibrosis of the skin, muscles, and internal organs.Â
Contraindication/Caution:Â
ContraindicationsÂ
CautionsÂ
Pregnancy consideration:Â Â
No data is available regarding the administration of the drug during pregnancy.Â
Breastfeeding warnings:Â Â
No data is available regarding the excretion of drug in breast milk.Â
Pregnancy category: CÂ
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: No data is available for the drug under this category.Â
Pharmacology:Â
Gadopentetate dimeglumine belongs to the gadolinium-based contrast agents (GBCAs) class of contrast agents. These medicines contain gadolinium, an element with unpaired electrons that can interact with the magnetic fields used in MRI. Gadopentetate dimeglumine improves the MRI signal when given intravenously, making it easier to see blood arteries, organs, and other structures. This is accomplished by modifying the relaxation periods of adjacent water molecules.Â
Pharmacodynamics:Â
Gadopentetate dimeglumine is a paramagnetic contrast agent. It comprises a gadolinium ion, which possesses unpaired electrons and thus is paramagnetic. In an MRI, gadolinium ions change the magnetic properties of the surrounding water molecules, resulting in increased signal intensity in T1-weighted images. This enhanced signal improves visualization of blood vessels, organs, and disease abnormalities.Â
Pharmacokinetics:Â
AbsorptionÂ
Limited information is available.Â
DistributionÂ
The volume of distribution of betrixaban is 266 mL/kgÂ
MetabolismÂ
Limited information is available.Â
Elimination and ExcretionÂ
The half-life is 1.6 hoursÂ
The drug is excreted 91% in urine.Â
Administration:Â
Gadopentetate dimeglumine is a gadolinium-based contrast agent used in medical imaging, namely magnetic resonance imaging (MRI). It is frequently sold under brand names like Magnevist. It is injected into a vein in an intravenous (IV) setting. The patient should be evaluated for any allergies, conditions that would call for extra care, or contraindications before receiving gadopentetate dimeglumine.
It is necessary to set up an appropriate intravenous (IV) line, typically in a vein in the patient’s hand or arm. For optimal performance, the IV line needs to be flushed with saline and securely fastened. An intravenous infusion of gadopentetate dimeglumine solution is given slowly. Although it can vary, the injection rate is usually regulated to guarantee image quality and patient safety.Â
Patient information leafletÂ
Generic Name: gadopentetate dimeglumineÂ
Pronounced: gad-oh-PEN-te-tate-dye-MEG-loo-meenÂ
Why do we use gadopentetate dimeglumine?Â
Magnetic characteristics are shown by the contrast agent gadopentetate dimeglumine. When used with magnetic resonance imaging (MRI), it improves the visibility of blood vessels, organs, and other non-bony structures.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
